UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 9, 2006
IMCLONE SYSTEMS INCORPORATED
(Exact name of registrant as specified in its charter)
Delaware |
| 0-19612 |
| 04-2834797 |
(State or other jurisdiction of |
| (Commission File Number) |
| (IRS Employer Identification No.) |
180 Varick Street
New York, New York 10014
(Address of principal executive offices) (Zip Code)
(212) 645-1405
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
On February 9, 2006, ImClone Systems Incorporated (the “Company”) announced that Richard Crowley, age 49, has been promoted to Senior Vice President, Biopharmaceutical Operations. In this role, Mr. Crowley will oversee the Company’s biologics manufacturing operations, which include the manufacturing, process development, engineering and facilities, quality control and quality assurance departments. Mr. Crowley joined the Company in 2000 as Assistant Vice President, Manufacturing, and was promoted to Vice President, Manufacturing and General Manager in 2002. Mr. Crowley replaces Joseph Tarnowski, Ph.D., Senior Vice President, Manufacturing Operations and Product Development, as head of the Company’s manufacturing operations. Dr. Tarnowski is leaving the Company to take a position at Bristol-Myers Squibb.
Before joining the Company in 2000, Mr. Crowley served in a variety of positions at BASF, Genencor International, Eastman Kodak and Monsanto. Most recently, he served as Director of Biologics Manufacturing at BASF Bioresearch Corp., where he was responsible for the construction and operation of a multi-product GMP clinical pilot/production facility for the production of biopharmaceuticals.
The text of the related press release, which is attached as Exhibit 99.1, is incorporated by reference herein in its entirety.
2
ITEM 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Description | |
|
|
|
99.1 |
| Press Release of ImClone Systems Incorporated dated February 9, 2006. |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IMCLONE SYSTEMS INCORPORATED | |||
| (Registrant) | |||
|
| |||
|
| |||
| By: | /s/ Erik D. Ramanathan |
| |
Dated: February 10, 2006 |
| Erik D. Ramanathan | ||
|
| Vice President, General Counsel | ||
4